Mupirocin: Product Information

MUPIROCIN- mupirocin ointment
Taro Pharmaceuticals U.S.A., Inc.

For dermatologic use on dogs


Federal law restricts this drug to use by or on the order of a licensed veterinarian.


Each gram of mupirocin ointment contains 20 mg of mupirocin in a bland, water-washable ointment base consisting of polyethylene glycol 400 and polyethylene glycol 3350 (polyethylene glycol ointment). Mupirocin is a naturally-occurring, broad-spectrum antibiotic. The chemical name is 9-4-[5S-(2S,3S-epoxy-5S-hydroxy-4S-methylhexyl)-3R,4R-dihydroxytetrahydropyran-2S-yl]-3-methylbut-2(E)-enoyloxy-nonanoic acid. The chemical structure is:

Chemical Structure
(click image for full-size original)


Mupirocin is a chemical entity produced by fermentation of the organism Pseudomonas fluorescens. Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-RNA synthetase. Due to this mode of action, mupirocin shows no cross resistance with chloramphenicol, erythromycin, gentamicin, lincomycin, neomycin, novobiocin, penicillin, streptomycin, and tetracycline. Mupirocin is an antimicrobial agent that inhibits the growth of gram-positive and gram-negative bacteria.

Bacteria susceptible to the action of mupirocin in vitro include the aerobic isolates of Staphylococcus aureus (including methicillin-resistant strains and β-lactamase-producing strains), Staphylococcus intermedius, Staphylococcus epidermidis , other coagulase positive or negative Staphylococci, α-hemolytic Streptococci, β group A Streptococci (including S. pyogenes) , other β Streptococci (including S. agalactiae) , group D Streptococci (including S. faecalis and S. faecium) , group Viridans Streptococci, Streptococcus pneumoniae, Corynebacterium hofmanii, Bacillus subtilis, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Proteus vulgaris, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii, Hemophilus influenzae (including β-lactamase-producing strains), Neisseria gonorrheae (including β-lactamase-producing strains), Neisseria meningitidis, Branhamella catarrhalis and Pasteurella multocida , and the anaerobic isolates of Peptostreptococcus anaerobius, Clostridium difficile, and Clostridium sporogenes.

Clinical significance of the in vitro data is unknown except for susceptible strains of Staphylcoccus aureus and Staphylococcus intermedius.


Mupirocin ointment is indicated for the topical treatment of canine bacterial infections of the skin, including superficial pyoderma, caused by susceptible strains of Staphylococcus aureus and Staphylococcus intermedius.


This drug is contraindicated in animals with a history of sensitivity reactions to any of its components.


Because of the potential hazard of nephrotoxicity due to the polyethylene glycol content of the base, care should be exercised when using this product in treating extensive deep lesions where absorption of large quantities of polyethylene glycol is possible.

Safety of use in pregnant or breeding animals has not been determined.

Mupirocin ointment is not for ophthalmic use.


No adverse reactions have been reported with this product. If a skin reaction such as irritation should occur, treatment should be discontinued and appropriate therapy instituted.


Prior to treatment, the lesion should be cleansed. Mupirocin ointment should be applied to the affected area twice a day. Apply a sufficient amount of ointment to completely cover the infected area. Maximum duration of treatment should not exceed 30 days.


Mupirocin ointment is supplied in 5 g, 15 g, 22 g, and 30 g tubes.

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]

Keep Out of Reach of Children

Approved by FDA under ANADA # 200-457

Mfd. by: Taro Pharmaceuticals Inc. Brampton, Ontario, Canada L6T 1C1

Dist. by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532

Revised: January 2020




NDC 51672-1354-0

Ointment USP, 2%

For dermatologic use on dogs.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Approved by FDA under ANADA # 200-457

Net Weight
22 g

Keep Out of Reach of Children.


(click image for full-size original)
mupirocin ointment
Product Information
Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:51672-1354
Route of Administration TOPICAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Mupirocin (Mupirocin) Mupirocin 20 mg in 1 g
Inactive Ingredients
Ingredient Name Strength
polyethylene glycol 400
polyethylene glycol 3350
Product Characteristics
Color WHITE (cream-like) Score
Shape Size
Flavor Imprint Code
# Item Code Package Description Multilevel Packaging
1 NDC:51672-1354-5 1 TUBE in 1 CARTON contains a TUBE
1 5 g in 1 TUBE This package is contained within the CARTON (51672-1354-5)
2 NDC:51672-1354-1 1 TUBE in 1 CARTON contains a TUBE
2 15 g in 1 TUBE This package is contained within the CARTON (51672-1354-1)
3 NDC:51672-1354-0 1 TUBE in 1 CARTON contains a TUBE
3 22 g in 1 TUBE This package is contained within the CARTON (51672-1354-0)
4 NDC:51672-1354-2 1 TUBE in 1 CARTON contains a TUBE
4 30 g in 1 TUBE This package is contained within the CARTON (51672-1354-2)
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANADA ANADA200457 11/29/2010
Labeler — Taro Pharmaceuticals U.S.A., Inc. (145186370)
Name Address ID/FEI Operations
Taro Pharmaceuticals Inc. 206263295 MANUFACTURE
Name Address ID/FEI Operations
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd 654019884 API MANUFACTURE
Name Address ID/FEI Operations
Teva Pharmaceutical Works Private Limited Company 366709764 API MANUFACTURE

Revised: 06/2020 Taro Pharmaceuticals U.S.A., Inc. provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the U.S. Food and Drug Administration. Package information is not reviewed or updated separately by Every individual animal healthcare product label entry contains a unique identifier which can be used to secure further details directly from the U.S. National Institutes of Health and/or the FDA.

Our database mirrors the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. provides the full animal health subset of the FDA's repository. Veterinary information provided here is not intended as a substitute for direct consultation with a qualified veterinary professional.

Terms of Use | Copyright © 2020. All Rights Reserved.